We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

VKTX stock opened at $30.48 on Thursday. Viking Therapeutics has a fifty-two week low of $28.64 and a fifty-two week high of $99.41. The business’s 50-day moving average is $37.97 and its two ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

In trading on Thursday, shares of Viking Therapeutics Inc (Symbol: VKTX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.81 per share.

Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...